Evaluation of the HeartLogic Diagnostic in Optimizing Guideline-directed Medical Therapy in Patients With Congestive Heart Failure and Chronically Low Ejection Fractions (EFs)

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRobert Pickett

About this trial

The goal of this trial is to determine if the addition of the Heart Logic diagnostic alerts to standard of care therapies will lessen hospitalizations and improve quality of life in patients with heart failure.

Eligibility criteria

Qualifiers

Age 18 years or older

EF </=35%

Prior hospitalization within the last two years or prior decompensation to NYHA class III or IV over the last 12 months that was treated without hospitalization

HeartLogic capable ICD or CRT-D (Patients with HeartLogic capable ICD or CRT-D can be enrolled at time of de novo implantation or generator change out or at the time of the 2 week wound check. Prior Heart logic capable ICF or CRT-D implants can be enrolled if heart failure hospitalization shows decompensation within six months (prior implants must have at least 1 year battery life)

Disqualifiers

Refuse to give consent

Have Life expectancy of less than one-year

Documented noncompliance that limits medication use

Patients on Dialysis (renal insufficiency but not on dialysis is NOT an exclusion)

Trial design

Treatments tested in this trial

  • Heartlogic Diagnostic Tool Threshold Change
  • Heartlogic Diagnostic Tool Unchanged Threshold

Treatment groups

135 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Robert Pickett

Lead sponsor

Ascension Health

Sponsor institution

Boston Scientific Corporation

Collaborator

Ascension Health

Collaborator